Form 4: Stitch Fix Officer Sells Shares After Option Exercise
Insider Transaction Report
Stitch Fix Chief Product/Technology Officer Anthony Bacos exercised stock options and subsequently sold 90,000 shares of Class A Common Stock under a pre-arranged 10b5-1 plan.
Summary
- Anthony Bacos, Chief Product/Technology Officer of Stitch Fix, Inc., exercised 60,000 employee stock options at an exercise price of $3.99 per share.
- Following the option exercise, Mr. Bacos sold a total of 90,000 shares of Class A Common Stock.
- The first sale involved 60,000 shares at a weighted average price of $5.6135 per share.
- The second sale involved 30,000 shares at a weighted average price of $5.6141 per share.
- All transactions were conducted on September 19, 2025, pursuant to a Rule 10b5-1 plan established on March 13, 2025.
- After these transactions, Mr. Bacos beneficially owns 799,966 shares of Class A Common Stock directly and 602,543 derivative securities (employee stock options).
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to a significant reduction in direct insider ownership, even though the transaction was pre-planned under a Rule 10b5-1 plan. The officer realized a profit, which is positive for the individual, but the net sale of shares can be perceived as a lack of increasing conviction in the company's near-term stock performance.
Positives
- The officer realized a profit by selling shares at prices significantly higher than the exercise price of the options ($5.61 vs. $3.99).
Negatives
- A significant reduction in direct insider ownership, with 90,000 shares sold, which could be perceived negatively by some investors.
Future Outlook
The filing indicates future vesting schedules for the remaining employee stock options, with shares vesting in equal quarterly installments over the next two and four quarterly vesting dates, subject to continuous service.
Industry Context
This Form 4 filing reports an insider transaction, which is a routine disclosure for publicly traded companies. It does not provide broader industry context or trends.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Adoption of Trading Plan | The reported transactions were executed pursuant to a Rule 10b5-1 plan, which allows insiders to set up a pre-arranged schedule for buying or selling company stock to avoid accusations of insider trading. | 2025-03-13 | Enhances transparency and provides an affirmative defense against insider trading allegations for the reporting person, indicating a planned rather than opportunistic sale. |
Stakeholder Impact
- Shareholders may interpret the insider's sale of shares as a signal, potentially leading to a cautious outlook, despite the pre-planned nature of the transaction.
- The officer benefits financially from the exercise and sale of options at a profit.
Next Steps
- Remaining employee stock options will vest in equal quarterly installments over the next two and four quarterly vesting dates, contingent on the reporting person's continuous service.
Key Dates
| Date | Description |
|---|---|
| 2024-06-12 | 25% of the shares subject to the option vested. |
| 2025-03-13 | Date the Rule 10b5-1 plan was entered into for the reported transactions. |
| 2025-09-19 | Date of option exercise and subsequent sale transactions. |
| 2025-09-22 | Date the Form 4 was signed by the Attorney-in-Fact for Anthony Bacos. |
| 2033-12-07 | Expiration date of the employee stock options. |
Recommendation
holdThe transaction is a pre-planned insider sale under a Rule 10b5-1 plan, which typically reduces the immediate signaling effect compared to an unplanned sale. While it represents a reduction in insider ownership, it does not necessarily indicate a change in the company's fundamental outlook or warrant a strong buy/sell recommendation based solely on this filing. Investors should consider this as a routine executive compensation event rather than a strong directional signal, maintaining a 'hold' position unless other fundamental factors change.
Keywords
Stitch Fix, SFIX, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Executive Compensation, Share Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.